LianBio
NASDAQ:LIAN
LianBio
NASDAQ:LIAN
Price:
0.319 USD
-8.28%
Market Closed
Updated:
Jun 1, 2024
LianBio
Additional Paid In Capital
|
LianBio
Additional Paid In Capital Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
LianBio
NASDAQ:LIAN
|
Additional Paid In Capital
$732.5m
|
CAGR 3-Years
342%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$20.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$6.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$7.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$11.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
See Also
What is LianBio's Additional Paid In Capital?
Additional Paid In Capital
732.5m
USD
732.5m
USD
Based on the financial report for Dec 31, 2022, LianBio's Additional Paid In Capital amounts to 732.5m USD.
What is LianBio's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
342%
342%
Over the last year, the Additional Paid In Capital growth was 3%. The average annual Additional Paid In Capital growth rates for LianBio have been 342% over the past three years .
You don't have any saved screeners yet
